natgillin/translations-raw huggingface dataset:
Levetiracetam ratiopharm oral solution may be diluted in a glass of water or baby’s bottle.
Peroralno raztopino zdravila Levetiracetam ratiopharm lahko razredčite v kozarcu vode ali steklenički za hranjenje.
Levetiracetam ratiopharm should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam ratiopharm med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion
Levetiracetam SUN 100 mg/ml koncentrat za raztopino za infundiranje
Levetiracetam SUN 100 mg/ml concentrate for solution for infusion Levetiracetam
Levetiracetam SUN 100 mg/ml koncentrat za raztopino za infundiranje Levetiracetam
Levetiracetam SUN 100 mg/ml sterile concentrate Levetiracetam
Levetiracetam SUN 100 mg/ml sterilni koncentrat levetiracetam
Levetiracetam SUN concentrate for solution for infusion (sterile concentrate) is a clear, colourless liquid.
Levetiracetam SUN koncentrat za raztopino za infundiranje (sterilni koncentrat) je bistra, brezbarvna, tekočina.
Levetiracetam SUN has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih zdravila Levetiracetam SUN, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na razmnoževanje.
Levetiracetam Sun is a ‘generic medicine’.
Levetiracetam Sun je „generično zdravilo“.
Levetiracetam SUN is indicated as adjunctive therapy
Zdravilo Levetiracetam SUN je indicirano za dopolnilno zdravljenje
Levetiracetam SUN is used
Zdravilo Levetiracetam SUN se uporablja:
Levetiracetam SUN may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Levetiracetam SUN lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko Levetiracetam SUN povzroči zaspanost.
Levetiracetam SUN should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam SUN med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam Teva 1,000 mg film-coated tablets
Levetiracetam Teva 1000 mg filmsko obložene tablete
Levetiracetam Teva 250 mg film-coated tablets Levetiracetam Teva 500 mg film-coated tablets Levetiracetam Teva 750 mg film-coated tablets Levetiracetam Teva 1,000 mg film-coated tablets
Levetiracetam Teva 250 mg filmsko obložene tablete Levetiracetam Teva 500 mg filmsko obložene tablete Levetiracetam Teva 750 mg filmsko obložene tablete Levetiracetam Teva 1000 mg filmsko obložene tablete
Levetiracetam Teva are available in pack sizes of 20, 30, 50, 60, 100, 120 and 200 film-coated tablets and 50 x 1 film-coated tablets in PVC/PVdC – aluminium perforated unit dose blisters.
Filmsko obložene tablete zdravila Levetiracetam Teva so na voljo v pakiranjih po 20, 30, 50, 60, 100, 120 in 200 tablet ter 50 x 1 filmsko obložena tableta v perforiranem pretisnem omotu iz PVC/PVdC- aluminija za enkratni odmerek.
Levetiracetam Teva has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.
Študije na živalih so pri odmerkih zdravila Levetiracetam Teva, ki so višji kot je potrebno za nadzor napadov, pokazale neželene učinke na razmnoževanje.
Levetiracetam Teva is a ‘generic medicine’.
Levetiracetam Teva je „generično zdravilo“.
Levetiracetam Teva is indicated as adjunctive therapy
Zdravilo Levetiracetam Teva je indicirano za dopolnilno zdravljenje
Levetiracetam Teva is not indicated in children and adolescents below 16 years on its own (monotherapy).
Zdravilo Levetiracetam Teva pri otrocih in mladostnikih, mlajših od 16 let, ni indicirano za samostojno zdravljenje (monoterapija).
Levetiracetam Teva is used as a chronic treatment.
Zdravilo Levetiracetam Teva se uporablja za dolgotrajno zdravljenje.
Levetiracetam Teva may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy.
Zdravilo Levetiracetam Teva lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali strojev, saj lahko povzroči zaspanost.
Levetiracetam Teva should not be used during pregnancy unless clearly necessary.
Zdravila Levetiracetam Teva med nosečnostjo ne smete uporabljati, razen kadar je nedvomno potrebno.
Levetiracetam therapy can be initiated with either intravenous or oral administration.
Zdravljenje z zdravilom Keppra lahko začnemo z intravensko ali peroralno uporabo.
Levitra 10 mg film-coated tablets
Levitra 10 mg filmsko obložene tablete vardenafil
Levitra 10 mg orodispersible tablet is not bioequivalent to Levitra 10 mg film-coated tablet (see section 5.1).
Zdravilo Levitra 10 mg orodisperibilne tablete ni bioekvivalentno z zdravilom Levitra 10 mg filmsko obložene tablete (glejte poglavje 5.1).
Levitra 10 mg orodispersible tablets
Levitra 10 mg orodisperzibilne tablete vardenafil
Levitra 10 mg orodispersible tablets contain aspartame, a source of phenylalanine which may be harmful for people with phenylketonuria.
Zdravilo Levitra 10 mg orodisperzibilne tablete vsebuje aspartam, vir fenilalanina, ki lahko škoduje ljudem s fenilketonurijo.
Levitra 10 mg orodispersible tablets contain sorbitol.
Zdravilo Levitra 10 mg orodisperzibilne tablete vsebuje sorbitol.
Levitra 10 mg orodispersible tablets contains Aspartame and Sorbitol.
Zdravilo Levitra 10 mg orodisperzibilne tablete vsebuje aspartam in sorbitol.
Levitra 20 mg film-coated tablets
Levitra 20 mg filmsko obložene tablete vardenafil
Levitra 5 mg film-coated tablets
Levitra 5 mg filmsko obložene tablete vardenafil
Levitra can be taken with or without food.
Tablete zdravila Levitra se lahko jemlje s hrano ali brez nje.
Levitra is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous phosphodiesterase 5 (PDE5) inhibitor exposure (see section 4.4).
Zdravilo Levitra je kontraindicirano pri bolnikih, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če le-ta ni bila povezana s predhodnim jemanjem zaviralcev fosfodiesteraze 5 (PDE5) (glejte poglavje 4.4).
Levitra is not for use by women.
Zdravilo Levitra ni namenjeno ženskam.
Levitra is not intended for use by children or adolescents under 18.
Zdravilo Levitra ni namenjeno otrokom ali mladostnikom, mlajšim od 18 let.
Levitra might make some people feel dizzy or affect their vision.
Pri nekaterih ljudeh lahko zdravilo Levitra povzroči vrtoglavico ali motnje vida.
Levitra must not be taken with ketoconazole and itraconazole (used to treat fungal infections) in men over 75 years of age, or with medicines called ‘HIV protease inhibitors’ such as ritonavir or indinavir (used to treat HIV infection).
Zdravilo Levitra se ne sme jemati s ketokonazolom in itrakonazolom (zdravili za zdravljenje glivičnih okužb) pri moških, starejših od 75 let, ali zdravili, imenovanimi „zaviralci proteaz HIV“, kot na primer ritonavir ali indinavir (zdravili za zdravljenje okužbe z virusom HIV).
Levitra with food, drink and alcohol
Zdravilo Levitra skupaj s hrano, pijačo in alkoholom
Levodopa adjustments during Tasmar treatment:
Prilagajanje odmerka levodope med zdravljenjem z zdravilom Tasmar
Levodopa adjustments when Tasmar is discontinued:
Prilagajanje odmerka levodope ob prekinitvi zdravljenja z zdravilom Tasmar
Levodopa competes with certain amino acids for transport, therefore high protein meals may impair the absorption of levodopa.
Med levodopo in nekaterimi aminokislinami obstaja kompeticija pri transportu, zato obroki z veliko vsebnostjo beljakovin lahko zmanjšajo absorpcijo levodope.
Levodopa crosses the blood-brain barrier by active transporters for large neutral amino acids.
Levodope prehaja krvno- možgansko pregrado prek transportnih beljakovin za velike nevtralne aminokisline.
Levodopa has been associated with somnolence and episodes of sudden sleep onset (see section 4.7).
Levodope je povezana s somnolenco in epizodami nenadnega nastopa spanca (glejte poglavje 4.7).
Levodopa increases the amount of dopamine and hence reduces the symptoms of Parkinson’s disease.
Levodopa povečuje količino dopamina in tako zmanjša simptome Parkinsonove bolezni.
Levodopa is bound to plasma protein only to a minor extent of about 10-30% and carbidopa is bound approximately 36%, while entacapone is extensively bound to plasma proteins (about 98%) –mainly to serum albumin.
Levodopa se le v manjši meri veže na proteine v plazmi (približno 10-30 %), karbidopa pa v približno 36 %, med tem ko se entakapon veže na proteine v plazmi v veliki meri (približno 98 %) - in to pretežno na serumski albumin.
Levodopa is bound to plasma protein only to a minor extent of about 10-30% and carbidopa is bound approximately 36%, while entacapone is extensively bound to plasma proteins (about 98%) –mainly to serum albumin.
Levodopa se le v manjši meri veže na proteine v plazmi (približno 10-30 %), karbidopa pa v približno 36 %, med tem ko se entakapon veže na proteine v plazmi v veliki meri (približno 98 %) - pretežno na serumski albumin.
Levodopa is bound to plasma protein only to a small extent (10-30%).
Levodope se v majhni meri veže na beljakovine v plazmi (10–30 %).
levodopa is extensively metabolised in the periphery, only a small portion of a given dose reaches the central nervous system when levodopa is administered without metabolic enzyme inhibitors.
Ker se levodopa večinoma presnavlja periferno, le majhen delež odmerka doseže osrednji živčni sistem, kadar se levodopa uporablja brez zaviralcev encimov, ki sodelujejo pri presnovi.
Levodopa-naïve patients with Parkinson’s disease APEX-PD
Bolniki s Parkinsonovo boleznijo, ki še niso prejemali levodope APEX-PD
Levodopa/Carbidopa/Entacapone
EU/1/11/706/025
Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg: brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg so rjavkaste ali sivkasto- rdečkaste filmsko obložene ovalne tablete brez zareze, z oznako »LCE 100« na eni strani.
Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg: light brownish red, oval film- coated tablets marked with ‘LCE 125’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg: svetlorjavkasto rdeče, ovalne tablete z oznako »LCE 125« na eni strani.
Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg: brownish or greyish red, elongated- ellipse shaped, unscored film-coated tablets marked with ‘LCE 150’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg so rjavkaste ali sivkasto- rdeče, podolgovate filmsko obložene tablete v obliki elipse brez zareze, z oznako »LCE 150« na eni strani.
Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 175 mg/43,75 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg: light brownish red, oval, unscored film-coated tablets marked with ‘LCE 175’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 175 mg/43,75 mg/200 mg: svetlorjavkasto rdeče, ovalne tablete z oznako »LCE 175« na eni strani.
Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Levodopa/Carbidopa/Entacapone Orion200 mg/50 mg/200 mg filmsko obložene tablete levodopa/karbidopa/entakapon
Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg: dark brownish red, oval, unscored film-coated tablets marked with ‘LCE 200’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg: temno rjavo-rdeče ovalne filmsko obložene tablete brez zareze z oznako „LCE 200“ na eni strani.
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets levodopa/carbidopa/entacapone
Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg filmsko obložene tablete levodopa/karbidopa/entakapon
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg: brownish or greyish red, round, convex unscored film-coated tablets marked with ‘LCE 50’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg so rjavkaste ali sivkasto- rdeče, okrogle, konveksne filmsko obložene tablete brez zareze, z oznako »LCE 50« na eni strani.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg filmsko obložene tablete
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75’ on one side.
Zdravilo Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg: svetlorjavkasto rdeče, ovalne filmsko obložene tablete z oznako »LCE 75« na eni strani.
Levodopa/Carbidopa/Entacapone Orion contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase- isomaltase insufficiency should not take this medicine.
Zdravilo Levodopa/Carbidopa/Entacapone Orion vsebuje saharozo, zato bolniki z redkimi prirojenimi motnjami, kot so intoleranca za fruktozo, malabsorpcija glukoze-galaktoze ali pomanjkanje saharaze-izomaltaze, ne smejo jemati tega zdravila.
Levodopa/Carbidopa/Entacapone Orion contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet.
Zdravilo Levodopa/Carbidopa/Entacapone Orion vsebuje tri zdravilne učinkovine (levodopo, kabidopo in entakapon) v eni filmsko obloženi tableti.
Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Zdravilo Levodopa/Carbidopa/Entacapone Orion je indicirano odraslih bolnikih s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa-dekarboksilaze (DDK) ne stabilizira.
Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Zdravilo Levodopa/Carbidopa/Entacapone Orion je indicirano pri odraslih bolnikih s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa-dekarboksilaze (DDK) ne stabilizira.
Levodopa/Carbidopa/Entacapone Orion is not recommended for the treatment of drug-induced extrapyramidal reactions
Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne priporoča za zdravljenje ekstrapiramidnih reakcij, ki jih povzročajo zdravila.
Levodopa/Carbidopa/Entacapone Orion is used for the treatment of Parkinson’s disease.
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja za zdravljenje Parkinsonove bolezni.
Levodopa/Carbidopa/Entacapone Orion is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson’s disease) but are having ‘fluctuations’ towards the end of the period between two doses of their medication.
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja pri bolnikih, ki se zdravijo s kombinacijo levodope in zaviralca dopa dekarboksilaze (dveh običajnih zdravil za Parkinsonovo bolezen), pri katerih pa se proti koncu obdobja med dvema odmerkoma zdravila pojavijo fluktuacije.
Levodopa/Carbidopa/Entacapone Orion is used to treat adults with Parkinson’s disease.
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja za zdravljenje odraslih bolnikov s Parkinsonovo boleznijo.
Levodopa/Carbidopa/Entacapone Orion may have a major influence on the ability to drive and use machines.
Zdravilo Levodopa/Carbidopa/Entacapone Orion ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Levodopa/Carbidopa/Entacapone Orion may induce orthostatic hypotension.
Zdravilo Levodopa/Carbidopa/Entacapone Orion lahko povzroči ortostatsko hipotenzijo.
Levodopa/Carbidopa/Entacapone Orion must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors’ (a type of antidepressant).
Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne sme uporabljati skupaj z drugimi zdravili, ki spadajo v skupino zaviralcev monoaminooksidaze (vrsta antidepresivov).
Levodopa/Carbidopa/Entacapone Orion therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions.
Previdnost je potrebna tudi pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom z ishemično boleznijo srca, s hudim kardiovaskularnim ali pljučnim obolenjem, bronhialno astmo, boleznijo ledvic ali žlez z notranjim izločanjem, kot tudi tistim, ki so kdaj v preteklosti imeli želodčno razjedo ali konvulzije.
Levofloxacin
kaspofungin
Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.
Če se pri bolniku po začetku zdravljenja pojavijo simptomi nevropatije, je treba zdravljenje z levofloksacinom prekiniti, da stanje ne postane ireverzibilno.
Levonorgestrel 150 mcg QD
Levonorgestrel 150
Levonorgestrel 150 mcg QD (maraviroc 100 mg BID)
Levonorgestrel 150
Levonorgestrel-releasing intrauterine system
intrauterini sistem, ki sprošča levonorgestrel,
Levonorgestrel-releasing intrauterine system (IUS)
Intrauterini sistem (IUS), ki sprošča levonorgestrel
Levonorgestrel-releasing intrauterine system (IUS)
vsadek; intrauterini sistem (IUS), ki sprošča levonorgestrel;
Levothyroxin e
levotiroksin
levothyroxine (to stimulate the thyroid gland)
levotiroksin (za spodbujanje ščitnice)
Lexington MA 02421 USA
Lexington, MA 02421 ZDA
Lexington, MA 02421 USA
Lexington, MA 02421 ZDA
LFA-1/ICAM binding, efalizumab may alleviate signs and symptoms of psoriasis by inhibiting several stages in the immunologic cascade.
S preprečevanjem vezave LFA-1/ICAM, lahko efalizumab ublaži znake in simptome psoriaze z inhibicijo več stopenj imunološke kaskade.
LFTs should be performed prior to the initiation of treatment with Eucreas in order to know the patient’s baseline value.
Pred začetkom zdravljenja z zdravilom Eucreas je treba opraviti pregled jetrnih testov za določitev bolnikovih izhodiščnih vrednosti.
LFTs should be performed prior to the initiation of treatment with Icandra in order to know the patient’s baseline value.
Pred začetkom zdravljenja z zdravilom Icandra je treba opraviti pregled jetrnih testov za določitev bolnikovih izhodiščnih vrednosti.
LFTs should be performed prior to the initiation of treatment with Zomarist in order to know the patient’s baseline value.
Pred začetkom zdravljenja z zdravilom Zomarist je treba opraviti pregled jetrnih testov za določitev bolnikovih izhodiščnih vrednosti.
LG Life Sciences Ltd., Iksan Plant, 601 Yongje-dong, Iksan-si, Jeonbuk-do 570-350, South Korea Name and address of the manufacturer responsible for batch release
LG Life Sciences Ltd., Iksan Plant, 601 Yongje-dong, Iksan-si, Jeonbuk-do 570-350, Južna Koreja Ime in naslov izdelovalca, odgovornega za sproščanje serije
LH stimulates ovulation during your menstrual cycle.
LH stimulira ovulacijo med menstrualnim ciklusom.
LH stimulates the release of the eggs.
LH stimulira sproščanje jajčec.
LHON can lead to loss of eyesight due to the inactivity of cells responsible for vision.
Zaradi neaktivnosti celic, odgovornih za vid, lahko LHON povzroči izgubo vida.
LHRH controls another hormone, called LH (‘luteinising hormone’).
LHRH nadzoruje drug hormon, imenovan LH (‘luteinizirajoči hormon’).
Libertek 500 micrograms film-coated tablets are yellow, D-shaped film-coated tablets, embossed with 'D' on one side.
Libertek 500 mikrogramov filmsko obložene tablete so rumene barve, v obliki črke D in imajo na eni strani izbočeno črko “D”.
Libertek is not indicated as rescue medicinal product for the relief of acute bronchospasms.
Zdravilo Libertekni indicirano kot zdravilo za prvo pomoč pri zdravljenju akutnih bronhospazmov.
Libertek is not recommended if you have one or more of the following diseases: severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)
Zdravljenje z zdravilom Libertek ni priporočljivo, če imate eno ali več naslednjih bolezni: resne bolezni imunskega sistema, kot so okužba s HIV, multipla skleroza (MS), eritematozni lupus (EL) ali progresivna multifokalna levkoencefalopatija (PML),
Libertek is not recommended in patients with a history of depression associated with suicidal ideation or behaviour.
Zdravilo Libertek ni priporočljivo za bolnike z anamnezo depresije, ki je bila povezana s samomorilnimi mislimi ali vedenjem.
Libertek is not used on its own but as an ‘add-on’ to treatment with bronchodilators (medicines that widen the airways in the lungs).
Zdravilo Libertek se ne uporablja samostojno, ampak kot „dodatek“ k zdravljenju z bronhodilatorji (zdravili, ki širijo dihalne poti v pljučih).
Libertek should not be used by children and adolescents under 18 years of age.
Zdravilo Libertek se ne sme uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Libido decreased
zmanjšan libido
Libido decreased Mood altered
prememba razpoloženja
libido decreased myalgia
zmanjšanje spolne sle, mialgija.
Libido increased
zvečan libido
libido increased),
omnolenca
Licensed smallpox vaccine
Odobreno cepivo proti črnim kozam
lichenoid keratosis (lichen planus and lichen sclerosus)
lihenoidna keratoza (lichen planus in lichen sclerosus)
lichenoid keratosiso, psoriasis, alopecia, erythema nodosum, dermatitis, hair colour changes, papule
lihenoidna keratozao, psoriaza, alopecija, nodozni eritem, dermatitis, spremembe barve las/dlak, papule
LID OF TRAY CONTAINING 30 SINGLE-DOSE CONTAINERS
PLADENJ S 30 ENOODMERNIMI VSEBNIKI
lidocaine (intravenous)
lidokain (apliciran intravensko)
Lidocaine (systemic)
dronedaronom, sistemskim
Lidocaine (systemic)
ranolazin
Lidocaine (systemic) Mexiletine Propafenone Quinidine
lidokain (sistemski) meksiletin propafenon kinidin
Lidocaine (systemic) Quinidine Hydroquinidine (saquinavir/ritonavir)
bepridil, sistemski lidokain kinidin hidrokinidin (sakvinavir/ritonavir)
lidocaine given by injection
lidokain v obliki injekcij
Lidocaine infusion should be discontinued if the patient develops dizziness, perioral numbness, or tinnitus.
Infuzijo lidokaina je treba prekiniti, če bolnik kaže znake omotice, perioralne odrevenelosti ali tinitusa.
Lidocaine may be administered as an intravenous infusion (2 mg/kg in 50 mL of 0.9 % sodium chloride) over 30 minutes prior to the start of each dinutuximab infusion and continued via intravenous infusion at
Lidokain se lahko daje v obliki intravenske infuzije (2 mg/kg v 50 ml 0,9 % natrijevega klorida) 30 minut pred začetkom posamezne infuzije dinutuksimaba in se nadaljuje z dajanjem intravenske infuzije po
lidocaine, quinidine, or ranolazine is
lidokainom, kinidinom ali
Lie down or take deep breaths when feeling nauseous
Če občutite slabost, se ulezite ali globoko dihajte.
Liechtenstein
Suomi/Finland
Lietuva
369 (93%)
Lietuva (Lithuania) Generics [UK] Ltd Tel: + 44 1707 853000
Lietuva(Lithuania) Generics [UK] Ltd Tel: +44 1707 853 000